Holen Sie sich die Stockscreener-App
15.38
11.89%
-2.11
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference - GlobeNewswire
Tonix Pharma stock rises following TONIX ONE launch - Investing.com Australia
Tonix Pharma stock rises following TONIX ONE launch By Investing.com - Investing.com UK
Tonix Pharmaceuticals launches migraine management platform - Investing.com
Tonix Pharmaceuticals launches migraine management platform By Investing.com - Investing.com Canada
Tonix Pharmaceuticals Launches TONIX ONE™, a - GlobeNewswire
Game-Changing Digital Platform Transforms How Patients Track and Treat Migraines - Stock Titan
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year - ACCESS Newswire
Revolutionary Non-Opioid Pain Drug Could Transform Fibromyalgia Treatment by 2025 - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - Bluefield Daily Telegraph
(TNXP) Long Term Investment Analysis - Stock Traders Daily
Tonix Pharmaceuticals Announces Presentation at the - GlobeNewswire
Fast-Tracked Fibromyalgia Treatment: Tonix Showcases Breakthrough Pain Drug Data Before FDA Decision - StockTitan
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Pharma Frenzy: Volatility Ignites Biotech Sector - Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Tonix advances fibromyalgia drug, eyes Q4 2025 launch By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment; Shares Up - MarketScreener
Tonix advances fibromyalgia drug, eyes Q4 2025 launch - Investing.com India
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment - Marketscreener.com
Tonix Pharmaceuticals stock soars on FDA update By Investing.com - Investing.com Australia
Tonix Pharmaceuticals stock soars on FDA update - Investing.com
Tonix Pharma’s TNX-102 SL Advances in FDA Process - TipRanks
Tonix Pharmaceuticals Announces that FDA Will Not Require - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Advances: FDA Expedites TNX-102 SL Review - Stock Titan
Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish - MSN
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - BioSpace
New Single-Dose Mpox Vaccine Outperforms Existing Options as Cases Surge Worldwide - StockTitan
Tonix Pharma stock drops after Q4 revenue miss (TNXP:NASDAQ) - Seeking Alpha
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Reports 2024 Financial Results and Pipeline Progress - TipRanks
Tonix Pharmaceuticals stock tumbles on earnings miss - Investing.com India
Tonix Pharma earnings missed by $5.86, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals stock tumbles on earnings miss By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp. SEC 10-K Report - TradingView
Tonix Pharmaceuticals 8-K Filing Analysis - TradingView
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewswire
Tonix Secures Path to First New Fibromyalgia Drug in 15 Years with $98.8M War Chest - StockTitan
Learn to Evaluate (TNXP) using the Charts - Stock Traders Daily
* Tonix pharmaceuticals announces 1-for-10 reverse stock split - Reuters
Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development - Proactive Investors USA
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 - GlobeNewswire
Major FDA Decision Looms: Tonix's Revolutionary Fibromyalgia Treatment Could End 15-Year Innovation Drought - StockTitan
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target - BioSpace
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):